An effective screening with SRAdoc® identifies patients with previously unrecognized paroxysmal atrial fibrillation and can thus prevent strokes. In Germany alone, there are approximately 1 million people with unrecognized and untreated paroxysmal atrial fibrillation. SRAdoc® is used to identify these in good time and to initiate an adequate therapy.
Patients who show a risk for paroxysmal atrial fibrillation after SRAdoc® will be examined for fibrillation episodes with SRA24®. SRA24® automaticall finds occurring fibrillation episodes and saves the physician the time consuming search for them.
In patients with paroxysmal atrial fibrillation the probability to detect a fibrillation episode is increased with the prolongation of the recording time. But without a targeted pre-selection of the patients to be examined, the success to identify these patients will be kept within limits, even with recordings over several days.
Onepager Brochure User Report SRAdoc Report SRA24